Among the NSCLC patients harboring KRAS mutations, patients with the co-occurrence of SMARCA4 mutation had a reduced objective response rate (ORR) (0.0% vs. 23.5%, P = 0.02), progression-free survival (PFS) (1.7 months vs. 4.1 months, P < 0.001), and median OS (4.0 months vs. 14.9 months, P < 0.001). The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.